Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel therapies.

D E Trentham1

  • 1Harvard Medical School, Boston, Massachusetts.

Current Opinion in Rheumatology
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Preliminary findings suggest minocycline and T-cell therapies may benefit rheumatoid arthritis (RA). High-dose intravenous immunoglobulin shows potential for chronic cutaneous vasculitis.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amiprilose hydrochloride for the treatment of rheumatoid arthritis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Treatment of rheumatic disease by tumor necrosis factor-alpha blockade: knowns and unknowns.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2006
Same author

Minocycline in early diffuse scleroderma.

Lancet (London, England)·1998
Same author

Oral tolerization as a treatment of rheumatoid arthritis.

Rheumatic diseases clinics of North America·1998
Same author

Relapsing polychondritis.

Annals of internal medicine·1998
Same author

Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial.

Arthritis and rheumatism·1998
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Area of Science:

  • Immunology
  • Rheumatology
  • Dermatology

Background:

  • Rheumatoid arthritis (RA) and chronic cutaneous vasculitis are inflammatory conditions.
  • Current treatment options may have limitations or side effects.

Purpose of the Study:

  • To explore the potential efficacy of novel therapeutic strategies in autoimmune diseases.
  • To identify promising treatments for further clinical investigation.

Main Methods:

  • Uncontrolled feasibility studies were conducted.
  • Evaluated minocycline and T-cell cytolytic strategies for RA.
  • Assessed high-dose intravenous gammaglobulin for chronic cutaneous vasculitis.

Main Results:

  • Extremely preliminary results indicate potential benefits.
  • Minocycline and T-cell strategies warrant further study in RA.
  • High-dose intravenous gammaglobulin shows promise in chronic cutaneous vasculitis.

    • Conclusions:

    • These early findings suggest new avenues for treating RA and vasculitis.
    • Further controlled clinical trials are necessary to confirm efficacy and safety.